Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Candice Roberts

Nurse Practitioner, Family Georgetown, DE Nurse Practitioner

NPI 1851700686 CMS profile 10556412

18229 Dupont Blvd, Ste 101, Georgetown, DE 19947

Open in the dashboard

General payments

$8,043

172 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candice Roberts of Georgetown, DE is reported in the CMS Open Payments database as having received $8,043 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,058 12
2024 General $1,364 18
2023 General $1,634 26
2022 General $2,585 28
2021 General $1,401 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candice Roberts
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Candice Roberts were reported at $1,058. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Candice Roberts Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,401 $124 $35–$379 $132
2022 $2,585 $141 $44–$430 $149
2023 $1,634 $154 $49–$476 $160
2024 $1,364 $165 $51–$504 $164
2025 $1,058 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $3,879 38 payments
  2. Abbott Laboratories $2,339 22 payments
  3. Biohaven Pharmaceuticals, Inc. $816 51 payments
  4. Biodelivery Sciences International, Inc. $169 15 payments
  5. Collegium Pharmaceutical, Inc. $153 10 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $76 4 payments
  7. GRT US Holding, Inc. $71 4 payments
  8. SI-BONE, Inc. $70 2 payments
  9. Amgen Inc. $67 3 payments
  10. Eisai Inc. $64 4 payments
  11. Other $337 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,090 152 payments
  2. Travel and Lodging $3,845 18 payments
  3. Education $108 2 payments
Products named General payments · program years 2021–2025
  1. VANTA ADAPTIVESTIM $2,635 23 payments
  2. SYNCHROMEDII $1,095 13 payments
  3. PROCLAIM Structural Heart $924 7 payments
  4. PROCLAIM Neuromodulation $863 6 payments
  5. NURTEC ODT $848 53 payments
  6. OCTRODE $263 3 payments
  7. BELBUCA Chronic Pain $169 15 payments
  8. Qutenza $128 6 payments
  9. INTELLIS ADAPTIVESTIM $125 1 payment
  10. BELBUCA Opioid Analgesic $109 7 payments
  11. Other $936 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

5,423

Median for Nurse Practitioner: 389

Drug cost

$244,557

Median for Nurse Practitioner: $21,885

Branded share of claims

35.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 100 $49,254
Xtampza Er Oxycodone Myristate Brand 79 $33,780
Oxycodone Hcl Generic 1,199 $23,580
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 568 $18,198
Hysingla Er Hydrocodone Bitartrate Brand 22 $16,376
Movantik Naloxegol Oxalate Brand 40 $15,845
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 553 $14,403
Nucynta Tapentadol Hcl Brand 11 $13,279
Naloxone Hcl Generic 139 $9,309
Tramadol Hcl Er Tramadol Hcl Brand 137 $8,678

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $32
$32 — —
Qutenza
  • Averitas Pharma Inc. $31
$31 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record